Resources: From pneumoACTION to Now
PneumoACTION (PreventPneumo.org) was launched by the PneumoADIP team at Johns Hopkins Bloomberg School of Public Health and supported by GAVI. The site was a resource of evidence and tools for poliymakers, advocates and other key stakeholders working around the globe to fight childhood pneumonia and pneumococcal disease. As PneumoADIP has become IVAC, we want to preserve and update important resources that can be useful in working toward improved global health policies and their implementation.
Global Childhood Diseases
View-hub Report (June 2017): current global access to new childhood vaccines
The VIEW-hub report displays data and figures on the introduction status of Haemophilus influenzae type b (Hib) vaccine, pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in the 73 Gavi countries. Since March 2016, new additions to the VIEW-hub report are information on countries’ current product and dosing schedule for PCV, rotavirus vaccine, and IPV. The report describes: the number of countries that have introduced each vaccine or plan to in the future; global and Gavi rates of vaccine coverage and access; projected introduction dates for Gavi countries; and historical trends in the rate of global vaccine introduction.
Download the latest View-hub report (June 2017, pdf, 27 pages)
Download the latest View-hub figures (June 2017, slide-deck)
PCV Product Assessment
The availability of multiple pneumococcal vaccines, with overlapping but non-identical characteristics, including formulation, poses decision-making challenges. The purpose of the PCV Product Assessment is to assist countries in making informed decisions around PCV product choice; and to assist Gavi in making informed decisions about PCV product requests (including switches) by countries.
This technical document synthesizes the epidemiologic and biologic evidence regarding pneumococcal conjugate vaccine (PCV) products, and briefly summarizes the programmatic considerations surrounding performance, effectiveness, and impact for current PCV products: 10-valent (PCV10) and 13-valent (PCV13).
Download the PCV Product Assessment (April 2017, 162 pages)
Download the Brief Summary of the PCV Product Assessment (1 page)
Hib & Pneumococcal Vaccine Use
Vaccines are a critical tool for increasing child survival. Historically, vaccination has proven to be a safe, cost-effective option for dramatically reducing death and disability associated with many childhood diseases, such as pneumonia, measles and polio.
- Pneumococcal vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe pneumonia among children living in the developing world, and can also causes meningitis and sepsis.
- Hib vaccine is also available to protect children against Haemophilus influenzae type b (Hib), which is another major cause of severe pneumonia, as well as meningitis.
These vaccines have been used successfully primarily in industrialized countries to reduce the burden of child pneumonia. In recent years, great progress has been made in increasing access to these vaccines for children in developing countries as well. However, much work remains to ensure universal access to these life-saving interventions.
Vaccine Health Impact & Safety
Routine pneumococcal immunization programs in North America and pneumococcal conjugate vaccine (PCV) efficacy studies in Africa demonstrate that multi-valent PCVs have the potential to save millions of children worldwide. Learn more details about vaccine health impact and safety research from North America, The Gambia, South Africa and Rwanda.
Reports & Key Scientific Publications
From global reports to important peer-reviewed literature, see our list of publications by IVAC and partners on pneumococcus, Hib, and rotavirus, and more.
Country Fact Sheets
Tools & Databases
Detailed descriptions of pneumonia- and vaccine-related terms.